These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25199002)

  • 1. Mass treatment to eliminate tuberculosis from an island population.
    Hill PC; Dye C; Viney K; Tabutoa K; Kienene T; Bissell K; Williams BG; Zachariah R; Marais BJ; Harries AD
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):899-904. PubMed ID: 25199002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity.
    Mirzazadeh A; Kahn JG; Haddad MB; Hill AN; Marks SM; Readhead A; Barry PM; Flood J; Mermin JH; Shete PB
    PLoS One; 2021; 16(4):e0249012. PubMed ID: 33793612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Battling tuberculosis in an island context with a high burden of communicable and non-communicable diseases: epidemiology, progress, and lessons learned in Kiribati, 2000 to 2012.
    Hoy D; Kienene T; Reiher B; Roth A; Tira T; McKenzie J; Merilles OE; Viney K
    Int J Infect Dis; 2015 Jan; 30():135-41. PubMed ID: 25455798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latent tuberculosis infection in children and adolescents in Russia.
    Aksenova VA; Vasilyeva IA; Kasaeva TC; Samoilova AG; Pshenichnaya NY; Tyulkova TE
    Int J Infect Dis; 2020 Mar; 92S():S26-S30. PubMed ID: 32114196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response.
    Warsinske HC; Rao AM; Moreira FMF; Santos PCP; Liu AB; Scott M; Malherbe ST; Ronacher K; Walzl G; Winter J; Sweeney TE; Croda J; Andrews JR; Khatri P
    JAMA Netw Open; 2018 Oct; 1(6):e183779. PubMed ID: 30646264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.
    Bamrah S; Brostrom R; Dorina F; Setik L; Song R; Kawamura LM; Heetderks A; Mase S
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):912-8. PubMed ID: 25199004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review.
    Clifford V; He Y; Zufferey C; Connell T; Curtis N
    Tuberculosis (Edinb); 2015 Dec; 95(6):639-650. PubMed ID: 26515270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study.
    Hermans SM; Grant AD; Chihota V; Lewis JJ; Vynnycky E; Churchyard GJ; Fielding KL
    BMC Med; 2016 Mar; 14():45. PubMed ID: 27004413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predicted impact of tuberculosis preventive therapy: the importance of disease progression assumptions.
    Sumner T; White RG
    BMC Infect Dis; 2020 Nov; 20(1):880. PubMed ID: 33228580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California.
    Menzies NA; Parriott A; Shrestha S; Dowdy DW; Cohen T; Salomon JA; Marks SM; Hill AN; Winston CA; Asay GR; Barry P; Readhead A; Flood J; Kahn JG; Shete PB
    Am J Respir Crit Care Med; 2020 Feb; 201(3):356-365. PubMed ID: 31626560
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidemiology of recurrent tuberculosis in the United States, 1993-2010.
    Kim L; Moonan PK; Yelk Woodruff RS; Kammerer JS; Haddad MB
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):357-60. PubMed ID: 23321472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present-day treatment of tuberculosis and latent tuberculosis infection.
    Pérez-Camacho I; Rivero-Juárez A; Kindelán JM; Rivero A
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():41-6. PubMed ID: 21420566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis treatment outcome and its associated factors among people living with HIV and AIDS in Fako Division of Cameroon.
    Tanue EA; Nsagha DS; Njamen TN; Assob NJC
    PLoS One; 2019; 14(7):e0218800. PubMed ID: 31361755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection.
    Houben RM; Crampin AC; Ndhlovu R; Sonnenberg P; Godfrey-Faussett P; Haas WH; Engelmann G; Lombard CJ; Wilkinson D; Bruchfeld J; Lockman S; Tappero J; Glynn JR
    Int J Tuberc Lung Dis; 2011 Jan; 15(1):24-31. PubMed ID: 21276292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS.
    Gutierrez EB; Gomes V; Picone CM; Suga H; Atomiya AN
    HIV Med; 2009 Oct; 10(9):564-72. PubMed ID: 19785665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.
    Houben RM; Dodd PJ
    PLoS Med; 2016 Oct; 13(10):e1002152. PubMed ID: 27780211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of different interventions for latent tuberculosis infections in China: a model-based study.
    Wen Z; Li T; Zhu W; Chen W; Zhang H; Wang W
    BMC Infect Dis; 2022 May; 22(1):488. PubMed ID: 35606696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.